Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes

NCT ID: NCT00160160

Last Updated: 2009-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

440 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Type 2 Diabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

comparator trial hypertension diabetes blood pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

eprosartan/HCTZ

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* essential hypertension,
* diabetes type 2

Exclusion Criteria

* severe cardiovascular disease,
* grade 3 hypertension,
* secondary hypertension,
* abnormal liver enzymes
Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Solvay Pharmaceuticals

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Global Clinical Director Solvay

Role: STUDY_DIRECTOR

Solvay Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Site 26

Calgary, , Canada

Site Status

Site 27

Montreal, , Canada

Site Status

Site 30

Québec, , Canada

Site Status

Site 31

Thornhill, , Canada

Site Status

Site 28

Vancouver, , Canada

Site Status

Site 29

Winnipeg, , Canada

Site Status

Site 39

Holbæk, , Denmark

Site Status

Site 38

Roskilde, , Denmark

Site Status

Site 40

Viborg, , Denmark

Site Status

Site 4

Anzin, , France

Site Status

Site 3

Blois, , France

Site Status

Site 10

Chemellier, , France

Site Status

Site 11

Cholet, , France

Site Status

Site 15

Cholet, , France

Site Status

Site 16

Cholet, , France

Site Status

Site 14

La Jubaudière, , France

Site Status

Site 13

Le Mesnil-en-Vallée, , France

Site Status

Site 7

Mûrs-Erigné, , France

Site Status

Site 12

Saint Pierre Montlim, , France

Site Status

Site 9

Saumur, , France

Site Status

Site 8

Segré, , France

Site Status

Site 6

Thouars, , France

Site Status

Site 2

Tours, , France

Site Status

Site 5

Vieux-Condé, , France

Site Status

Site 20

Bad Muenster, , Germany

Site Status

Site 22

Flörsheim, , Germany

Site Status

Site 19

Kirweiler, , Germany

Site Status

Site 21

Lambrecht, , Germany

Site Status

Site 25

Lindau, , Germany

Site Status

Site 24

Lutherstadt, , Germany

Site Status

Site 18

Lüneburg, , Germany

Site Status

Site 17

Riesa, , Germany

Site Status

Site 23

Waldbrunn, , Germany

Site Status

Site 62

Bologna, , Italy

Site Status

Site 60

Napoli, , Italy

Site Status

Site 58

Padua, , Italy

Site Status

Site 59

Palermo, , Italy

Site Status

Site 63

Pavia, , Italy

Site Status

Site 61

Pisa, , Italy

Site Status

Site 64

Torino, , Italy

Site Status

Site 43

Ålesund, , Norway

Site Status

Site 42

Bergen, , Norway

Site Status

Site 44

Horten, , Norway

Site Status

Site 41

Skedsmokorset, , Norway

Site Status

Site 55

Badajoz, , Spain

Site Status

Site 51

Badalona, , Spain

Site Status

Site 56

Barcelona, , Spain

Site Status

Site 57

Barcelona, , Spain

Site Status

Site 54

Ciudad Real, , Spain

Site Status

Site 53

Granada, , Spain

Site Status

Site 52

Madrid, , Spain

Site Status

Site 48

Ängelholm, , Sweden

Site Status

Site 47

Gothenburg, , Sweden

Site Status

Site 46

Helsingborg, , Sweden

Site Status

Site 45

Kristianstat, , Sweden

Site Status

Site 50

Malmo, , Sweden

Site Status

Site 49

Stockholm, , Sweden

Site Status

Site 33

Aberdeen, , United Kingdom

Site Status

Site 36

Bath, , United Kingdom

Site Status

Site 37

Liverpool, , United Kingdom

Site Status

Site 34

Manchester, , United Kingdom

Site Status

Site 32

Oldham, , United Kingdom

Site Status

Site 35

Rugby, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada Denmark France Germany Italy Norway Spain Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2004-00703-18

Identifier Type: -

Identifier Source: secondary_id

S171.3.012

Identifier Type: -

Identifier Source: org_study_id